Clinical Trial Update: Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the TGF-beta receptor I inhibitor Vactosertib in combination with standard-of-care chemoradiotherapy for locally advanced esophageal ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Esophagogastrgic Junction
• Esophageal Adenocarcinoma

Drugs mentioned

• Vactosertib (Vactosertib)

Snippet

Sponsor: Sakti Chakrabarti | Conditions: Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma | Phase 2 | Status: RECRUITING